ArticleInternational journal of chronic obstructive pulmonary disease2025
Five-Year Survival and Associated Factors in COPD Patients in Colombia: A Retrospective Cohort Study.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A machine learning model for predicting short-term in-hospital mortality in acute myocardial infarction with coexisting chronic obstructive pulmonary disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory respiratory disorder characterized by persistent respiratory symptoms that negatively impact quality of life, reduce survival, and increase the risk of cardiovascular events. It is one of the leading causes of global morbidity and mortality. Methods: A retrospective cohort study was conducted in patients with a confirmed diagnosis of COPD based on spirometry (FEV1/FVC < 0.7), who received care between 2005 and 2020. Adults over 40 years of age were included. Clinical, sociodemographic, and treatment-related variables were collected. Five-year survival was estimated using Kaplan-Meier curves and stratified by age, sex, comorbidities, use of oxygen therapy, FEV1 ≤ 35%, and GOLD 2025 classification. The Log rank test was used to compare survival differences. Results: A total of 350 COPD patients were included; the mean age was 75.3 years (SD 11.77); 82.3% were over 65 years old and 56.6% were male. Five-year survival was 89.7%. No differences were observed between sexes (p = 0.558). Survival was lower in those over 65 years (87.9% vs 98.5%; p = 0.015), in patients with heart failure (78.4% vs 91.1%; p = 0.014), those using oxygen therapy (82.2% vs 94.6%; p = 0.002), and those with FEV1 ≤ 35% (88.8% vs 96.5%; p = 0.035). A trend toward lower survival was found in GOLD group E (84.9%) compared to GOLD A (93.3%) and B (87.7%) (p = 0.186). Conclusion: The five-year survival rate in this cohort was 89.7%. Lower survival was observed in patients over 65 years of age, with heart failure, on home oxygen therapy, and with FEV1 ≤ 35%. A trend toward lower survival was identified in the GOLD group E.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.